Vertex Pharmaceuticals Inc

詳細情報 Vertex Pharmaceuticals Inc 企業名

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

企業情報

企業コードVRTX

会社名Vertex Pharmaceuticals Inc

上場日Jul 24, 1991

設立日1989

最高経営責任者「CEO」Dr. Reshma Kewalramani

従業員数6100

証券種類Ordinary Share

決算期末Jul 24

本社所在地50 Northern Avenue

都市BOSTON

証券取引所NASDAQ Global Select Consolidated

国United States of America

郵便番号02210

電話番号16173416393

ウェブサイトhttps://www.vrtx.com/

企業コードVRTX

上場日Jul 24, 1991

設立日1989

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Stuart A. Arbuckle

Chief Operating Officer, Executive Vice President

61.30K

+158.88%

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

41.81K

+38.72%

Mr. Bruce I. Sachs

Lead Independent Director

40.00K

--

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.67K

+40.46%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

30.30K

+19.95%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

24.47K

--

Mr. Jonathan Biller, J.D.

Executive Vice President, Chief Legal Officer

17.61K

+5.74%

Mr. Lloyd A. Carney

Independent Director

7.12K

+12.60%

Dr. Sangeeta N. Bhatia, M.D., Ph.D.

Independent Director

4.83K

+8.93%

Ms. Jennifer J. Schneider

Independent Director

1.72K

+86.33%

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Stuart A. Arbuckle

Chief Operating Officer, Executive Vice President

61.30K

+158.88%

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

41.81K

+38.72%

Mr. Bruce I. Sachs

Lead Independent Director

40.00K

--

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.67K

+40.46%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

30.30K

+19.95%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

24.47K

--

収益内訳

通貨: USD更新時刻: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

事業別USD

会社名

収益

比率

TRIKAFTA

10.24B

92.91%

Other CF products

781.50M

7.09%

地域別USD

会社名

収益

比率

United States

6.68B

60.66%

Europe

3.45B

31.34%

Other

881.30M

8.00%

事業別

地域別

事業別USD

会社名

収益

比率

TRIKAFTA

10.24B

92.91%

Other CF products

781.50M

7.09%

株主

更新時刻: Thu, May 15

株主統計

種類

株主統計

比率

Capital World Investors

11.11%

The Vanguard Group, Inc.

9.10%

Capital Research Global Investors

5.66%

BlackRock Institutional Trust Company, N.A.

5.45%

State Street Global Advisors (US)

4.59%

Other

64.08%

株主統計

比率

Capital World Investors

11.11%

The Vanguard Group, Inc.

9.10%

Capital Research Global Investors

5.66%

BlackRock Institutional Trust Company, N.A.

5.45%

State Street Global Advisors (US)

4.59%

Other

64.08%

種類

株主統計

比率

Investment Advisor

50.56%

Investment Advisor/Hedge Fund

37.18%

Research Firm

2.55%

Pension Fund

2.43%

Bank and Trust

2.04%

Sovereign Wealth Fund

1.47%

Hedge Fund

1.30%

Insurance Company

0.17%

Individual Investor

0.15%

Other

2.16%

機関投資家保有株

更新時刻: Sun, Jan 19

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q1

2908

248.19M

96.64%

-1.58M

2024Q4

2877

248.76M

96.87%

-2.25M

2024Q3

2786

247.87M

96.18%

-4.19M

2024Q2

2747

248.36M

96.27%

-4.14M

2024Q1

2680

247.63M

95.87%

-4.48M

2023Q4

2608

247.92M

96.20%

-4.51M

2023Q3

2477

248.64M

96.45%

-6.19M

2023Q2

2488

248.89M

96.55%

-7.11M

2023Q1

2468

250.11M

97.13%

-4.74M

2022Q4

2454

248.59M

96.73%

-7.80M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Capital World Investors

28.33M

11.02%

+1.51M

+5.65%

Dec 31, 2024

The Vanguard Group, Inc.

23.15M

9%

+102.48K

+0.44%

Dec 31, 2024

Capital Research Global Investors

10.43M

4.06%

+1.43M

+15.85%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

14.33M

5.57%

-90.57K

-0.63%

Dec 31, 2024

State Street Global Advisors (US)

11.98M

4.66%

+163.16K

+1.38%

Dec 31, 2024

Fidelity Management & Research Company LLC

9.11M

3.54%

-1.25M

-12.07%

Dec 31, 2024

Geode Capital Management, L.L.C.

5.65M

2.2%

-287.65K

-4.85%

Dec 31, 2024

Wellington Management Company, LLP

5.92M

2.3%

+1.12M

+23.28%

Dec 31, 2024

Invesco Capital Management (QQQ Trust)

5.33M

2.07%

+71.48K

+1.36%

Feb 28, 2025

JP Morgan Asset Management

4.62M

1.8%

-403.93K

-8.04%

Dec 31, 2024

詳細を見る

445.820USD

Vertex Pharmaceuticals Inc

445.820

概要

企業名